search
Back to results

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Primary Purpose

Duchenne Muscular Dystrophy (DMD)

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Prednisone
Placebo
Sponsored by
Ann & Robert H Lurie Children's Hospital of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Duchenne Muscular Dystrophy (DMD) focused on measuring Duchenne Muscular Dystrophy, Corticosteroids

Eligibility Criteria

3 Years - 6 Years (Child)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Genetically confirmed dystrophin mutation compatible with DMD phenotype. Specifically, gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame' OR showing complete absence of dystrophin by muscle biopsy.
  • Ages between 3 years and < 7 years
  • Steroid-naïve
  • Signed informed consent

Exclusion Criteria:

  • Treatment with CoenzymeQ10, creatine, amino acid supplements within 3 months of study entry
  • Treatment with cardiac medications: beta-blockers, digoxin, and carvedilol
  • Existing medical condition or physical disability that would alter subject's motor development
  • Existing medical condition that precludes the use of corticosteroids
  • Inability to swallow sample tablet in bite of soft food*
  • Investigator assessment that participant or family will not be compliant with treatment or study procedures
  • Been on investigational DMD medication for the past 6 months

Sites / Locations

  • Ann and Robert H. Lurie Children's Hospital of Chicago

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Placebo Comparator

Placebo Comparator

Arm Label

Immediate Release Prednisone

Delayed Release Prednisone

Placebo-Delayed Release Prednisone

Placebo-Immediate Release Prednisone

Arm Description

During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.

During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.

During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.

During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.

Outcomes

Primary Outcome Measures

Safety
The primary outcome will measure safety and tolerability by tabulating number of adverse events occuring in patients in each treatment group. Adverse events are specified in the protocol and relate to excess weight gain, inadequate linear growth, elevated blood pressure, worsening scores on behavior scales, declining heart rate variability and abnormalities of circadian rhythm of sympathetic tone.

Secondary Outcome Measures

Time to walk/run 50 meters
This test will measure the time it will take to run/walk 50 meters. It has not been typically used in clinical trials as a timed test measure, however, may be a more sensitive test measure in the very young cohort to assess functional strength as it measures a longer distance to run compared to the 10 meter walk. Preliminary analysis in a small pilot cohort indicates that it is better correlated with other functional assessments such as the North Star Ambulatory Assessment.
North Star Ambulatory Assessment (NSAA)
The NSAA is a clinician rated 17-item functional scale originally designed for ambulant boys with DMD who are able to ambulate at least 10 meters. This evaluation tool assesses functional activities including standing, getting up from the floor, negotiating steps, hopping, and running. The assessment is based on a 3-point rating scale of 2= ability to perform the test normally, 1= modified method or assistance to perform test, 0=unable to perform the test. Thus, total score can range from 0 (completely non-ambulant) to 34 (no impairment) on these assessments. NSAA has shown good reliability and validity in multi-center studies as well as good clinical validity demonstrated with Rasch analysis.

Full Information

First Posted
January 6, 2014
Last Updated
February 13, 2015
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators
Children's National Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02036463
Brief Title
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
Official Title
CINRG0513: A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
Study Type
Interventional

2. Study Status

Record Verification Date
February 2015
Overall Recruitment Status
Withdrawn
Why Stopped
No funding for project.
Study Start Date
November 2014 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators
Children's National Research Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease for which no curative treatment has yet been identified, making it important to slow progression and improve the quality of life among affected boys and young men. Treatment with corticosteroids is standard of care for patients with DMD five years old and older, due to the robust observation that this intervention lengthens the interval prior to loss of ambulation but is associated with many side effects. This clinical trial will be conducted in the youngest age group able to receive corticosteroids orally and on whom study outcomes are measurable, ages 3 to 7 years. This is a randomized, double blinded, double masked, placebo-controlled clinical trial that will explore whether better synchronization of corticosteroid administration with the circadian rhythm will provide improved tolerability and at least comparable efficacy to current standards in which corticosteroids are always given in the morning. Furthermore, the trial provides a unique opportunity to rigorously evaluate corticosteroid effects in the young DMD patient, both for efficacy as compared to placebo and as a study of the impact of corticosteroid chronotherapy, or delayed release, on increased tolerability over standard therapy. The main hypothesis is that synchronization of the timing of corticosteroid dosing will improve medication tolerability in children, while maintaining (non-inferiority) the efficacy of corticosteroid. The study also offers a unique opportunity to measure several biomarkers as well as novel genetic modifiers that may further impact the response to corticosteroid in DMD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Duchenne Muscular Dystrophy (DMD)
Keywords
Duchenne Muscular Dystrophy, Corticosteroids

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Immediate Release Prednisone
Arm Type
Active Comparator
Arm Description
During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
Arm Title
Delayed Release Prednisone
Arm Type
Experimental
Arm Description
During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
Arm Title
Placebo-Delayed Release Prednisone
Arm Type
Placebo Comparator
Arm Description
During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
Arm Title
Placebo-Immediate Release Prednisone
Arm Type
Placebo Comparator
Arm Description
During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
Intervention Type
Drug
Intervention Name(s)
Prednisone
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Safety
Description
The primary outcome will measure safety and tolerability by tabulating number of adverse events occuring in patients in each treatment group. Adverse events are specified in the protocol and relate to excess weight gain, inadequate linear growth, elevated blood pressure, worsening scores on behavior scales, declining heart rate variability and abnormalities of circadian rhythm of sympathetic tone.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Time to walk/run 50 meters
Description
This test will measure the time it will take to run/walk 50 meters. It has not been typically used in clinical trials as a timed test measure, however, may be a more sensitive test measure in the very young cohort to assess functional strength as it measures a longer distance to run compared to the 10 meter walk. Preliminary analysis in a small pilot cohort indicates that it is better correlated with other functional assessments such as the North Star Ambulatory Assessment.
Time Frame
18 months
Title
North Star Ambulatory Assessment (NSAA)
Description
The NSAA is a clinician rated 17-item functional scale originally designed for ambulant boys with DMD who are able to ambulate at least 10 meters. This evaluation tool assesses functional activities including standing, getting up from the floor, negotiating steps, hopping, and running. The assessment is based on a 3-point rating scale of 2= ability to perform the test normally, 1= modified method or assistance to perform test, 0=unable to perform the test. Thus, total score can range from 0 (completely non-ambulant) to 34 (no impairment) on these assessments. NSAA has shown good reliability and validity in multi-center studies as well as good clinical validity demonstrated with Rasch analysis.
Time Frame
18 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Genetically confirmed dystrophin mutation compatible with DMD phenotype. Specifically, gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame' OR showing complete absence of dystrophin by muscle biopsy. Ages between 3 years and < 7 years Steroid-naïve Signed informed consent Exclusion Criteria: Treatment with CoenzymeQ10, creatine, amino acid supplements within 3 months of study entry Treatment with cardiac medications: beta-blockers, digoxin, and carvedilol Existing medical condition or physical disability that would alter subject's motor development Existing medical condition that precludes the use of corticosteroids Inability to swallow sample tablet in bite of soft food* Investigator assessment that participant or family will not be compliant with treatment or study procedures Been on investigational DMD medication for the past 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nancy Kuntz, MD
Organizational Affiliation
Ann & Robert H Lurie Children's Hospital of Chicago
Official's Role
Study Chair
Facility Information:
Facility Name
Ann and Robert H. Lurie Children's Hospital of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

We'll reach out to this number within 24 hrs